Title (en)

METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Title (de)

VERFAHREN ZUR VERWENDUNG VON UND ZUSAMMENSETZUNGEN MIT SELEKTIVEN ZYOTKIN-HEMMENDEN ARZNEIMITTELN ZUR BEHANDLUNG UND VERSORGUNG VON ERKRANKUNGEN DES ZENTRALEN NERVENSYSTEMS

Title (fr)

METHODES D'UTILISATION ET COMPOSITIONS COMPRENANT DES MEDICAMENTS SELECTIFS INHIBITOIRES DE CYTOKINE POUR LE TRAITEMENT ET POUR LA GESTION DE TROUBLES DU SYSTEME NERVEUX CENTRAL

Publication

EP 1605935 A4 20090520 (EN)

Application

EP 04717992 A 20040305

Priority

• US 2004006782 W 20040305
• US 45237403 P 20030306

Abstract (en)

[origin: WO2004080393A2] Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

IPC 1-7

A61K 31/4035

IPC 8 full level

A61K 31/553 (2006.01); A61K 31/554 (2006.01); A61K 45/06 (2006.01)

CPC (source: EP KR)

A61K 31/4035 (2013.01 - KR); A61K 31/553 (2013.01 - EP); A61K 31/554 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 1/08 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/08 (2017.12 - EP); A61P 25/14 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP)

Citation (search report)

• [E] WO 2005094218 A2 20051013 - CELGENE CORP [US], et al
• [X] WO 9501348 A2 19950112 - CELGENE CORP [US], et al
• [X] WO 0134606 A1 20010517 - CELGENE CORP [US], et al
• [PX] WO 03080048 A1 20031002 - CELGENE CORP [US], et al
• [X] WO 9906041 A1 19990211 - CELGENE CORP [US], et al
• [Y] WO 0149321 A1 20010712 - TOBINICK EDWARD L [US]
• [PX] US 6623736 B2 20030923 - TOBINICK EDWARD L [US]
• [X] WO 9708143 A1 19970306 - CELGENE CORP [US], et al
• [Y] SRIRAM KRISHNAN ET AL: "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SEP 2002, vol. 16, no. 11, September 2002 (2002-09-01), pages 1474 - 1476, XP002522289, ISSN: 1530-6860
• [Y] MOGI M ET AL: "Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 165, no. 1-2, 3 January 1994 (1994-01-03), pages 208 - 210, XP024375768, ISSN: 0304-3940, [retrieved on 19940103]
• See references of WO 2004080393A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL LT LV MK

DOCDB simple family (publication)

WO 2004080393 A2 20040923; WO 2004080393 A3 20041202; AU 2004220607 A1 20040923; AU 2004220607 B2 20090611; BR PI0408113 A 20060301; CA 2517845 A1 20040923; CN 1780616 A 20060531; CN 1780616 B 20100512; EP 1605935 A2 20051221; EP 1605935 A4 20090520; IL 170710 A0 20110801; JP 2006519875 A 20060831; KR 100831545 B1 20080521; KR 20050109971 A 20051122; MX PA05009435 A 20051123; NZ 542408 A 20090331; ZA 200507322 B 20070328

DOCDB simple family (application)

US 2004006782 W 20040305; AU 2004220607 A 20040305; BR PI0408113 A 20040305; CA 2517845 A 20040305; CN 200480011819 A 20040305; EP 04717992 A 20040305; IL 17071005 A 20050906; JP 2006509174 A 20040305; KR 20057016598 A 20050906; MX PA05009435 A 20040305; NZ 54240804 A 20040305; ZA 200507322 A 20040305